What is Context Therapeutics Inc.'s (CNTX) StockRank?

MoatMap's StockRank for Context Therapeutics Inc. (CNTX) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (37), Value (37), and Momentum (31) factor ranks across MoatMap's 19,000+ stock universe.

Does Context Therapeutics Inc. have an economic moat?

Context Therapeutics Inc. (CNTX) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Context Therapeutics Inc. a buy, hold, or sell?

MoatMap's current signal for Context Therapeutics Inc. (CNTX) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Context Therapeutics Inc. in?

Context Therapeutics Inc. (CNTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CNTX

STRONG SELLREMOVE

Context Therapeutics Inc. · Healthcare · United States · $260M · Avg Vol: $887K/d

StockRank

P/E (TTM)

—

ROE

-56.2%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Context Therapeutics is a micro-cap clinical-stage biotech company with no revenues and high binary clinical trial risk, making it unsuitable for a high-conviction quality portfolio.

COMPANY DESCRIPTION

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for various cancers, with a particular focus on women's oncology. Its competitive position relies on the successful progression of its pipeline candidates, including its lead asset, onapristone extended-release, through clinical trials to address unmet medical needs.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.93	-1.50	-0.46	-0.38	—
Shares	16M	16M	90M	92M	+475.5%
Debt	55,078	0	219,380	112,064	26.7%
Equity	35M	12M	95M	60M	20.3%
Op CF	-14M	-21M	-15M	-26M	—
Inv CF	-536,836	0	-15M	-2M	—
Fin CF	-102,071	0	109M	-15,268	—

PRICE (1M)-70.5%

SMA 50SMA 200

$0.68

RSI (14)

13.7

52W High

$3.62

From 52W High

0.2%

SCORE BREAKDOWN

Quality

ROIC

-65.7%9.5

ROE

-56.2%15.5

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-34.7%7.1

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.01x92.3

Current Ratio

8.96x84.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.7x66.0

P/FCF

—N/A

P/B

2.4x47.5

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

19%1.7

RS 6M

-43%26.8

SMA 50/200

1.28x93.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-3%19.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$260M

P/E (Forward)

-3.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CNTX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CNTX	Context Therapeutics Inc.(you)	$260M	16	STRONG SELL
CHRS	Coherus Oncology, Inc.	$255M	17	STRONG SELL
FHTX	Foghorn Therapeutics Inc.	$251M	16	STRONG SELL
VYGR	Voyager Therapeutics, Inc.	$236M	17	STRONG SELL
RNA	Atrium Therapeutics, Inc.	$229M	17	STRONG SELL
TRDA	Entrada Therapeutics, Inc.	$265M	13	STRONG SELL
IMRX	Immuneering Corporation	$327M	16	STRONG SELL
CAMP	CAMP4 THERAPEUTICS CORPORATION	$233M	13	STRONG SELL
KROS	Keros Therapeutics, Inc.	$225M	14	STRONG SELL
NVCT	Nuvectis Pharma, Inc.	$270M	22	SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Context Therapeutics Inc. (CNTX) — Stock Score Summary

Context Therapeutics Inc. (CNTX) has a MoatMap StockRank of 16/100 based on Quality (37/100), Value (37/100), and Momentum (31/100) factor scores. The current signal is STRONG SELL. Context Therapeutics is a micro-cap clinical-stage biotech company with no revenues and high binary clinical trial risk, making it unsuitable for a high-conviction quality portfolio.

Key Financial Metrics

Price	$0.68
Market Cap	$260M
P/E (Forward)	-3.22
Price/Book	2.45
Return on Equity	-56.2%
Return on Invested Capital	-65.7%
Debt/Equity	0.54
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-24M

Context Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Context Therapeutics Inc.’s (CNTX) StockRank?: MoatMap’s StockRank for Context Therapeutics Inc. (CNTX) is 16/100, with a Strong Sell signal. It is a composite of Quality (37), Value (37), and Momentum (31) factor ranks across MoatMap’s 19,000+ stock universe.
Does Context Therapeutics Inc. have an economic moat?: Context Therapeutics Inc. (CNTX) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Context Therapeutics Inc. a buy, hold, or sell?: MoatMap’s current signal for Context Therapeutics Inc. (CNTX) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Context Therapeutics Inc. in?: Context Therapeutics Inc. (CNTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).